Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884318 | 0.84 | ALDH1A1 (0.42) | GAAALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL22600368 | 0.81 | GAA (0.46) | GAARAPGEF4ALDH1A1MEN1KMT2A | |
| SCHEMBL25251576 | 0.79 | RAPGEF4 (0.41) | GAARAPGEF4ALDH1A1MEN1KMT2A | |
| SCHEMBL5303678 | 0.79 | KMT2A (0.46) | GAARAPGEF4ALDH1A1MEN1KMT2A | |
| SCHEMBL30382381 | 0.79 | RAPGEF4 (0.41) | GAARAPGEF4ALDH1A1MEN1KMT2A | |
| SCHEMBL28122921 | 0.76 | GAA (0.53) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL28122920 | 0.76 | GAA (0.53) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL8248072 | 0.76 | MAPT (0.54) | GAAALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL29909448 | 0.75 | — | — | |
| SCHEMBL2085402 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912529-B | Method for synthesizing indole compounds by catalyzing N-aryl amide compounds and vinylene carbonate with ruthenium | 成都大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113912529-A | Method for synthesizing indole compound by catalyzing N-aryl amide compound and vinylene carbonate with ruthenium | 成都大学 | 2022-01-11 | — | — | CN | disclosed |
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-15 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7560565-B2 | Method for preparing derivatives of 3-hydroxypicolinic acid | BAYER CROPSCIENCE SA (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | GAA 1232/4885RAPGEF4 425/4885ALDH1A1 173/4885 |
| US-20180071252-A1 | METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS | PTPRJ, PTPRCAP, PTPRC | GAA 2528/4885RAPGEF4 732/4885ALDH1A1 4735/4885 |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | GAA 3698/4885RAPGEF4 2965/4885ALDH1A1 1173/4885 |
| US-20100113452-A1 | COMPOUNDS FOR TREATING PULMONARY HYPERTENSION | PTGIR, PTGIS, EDNRB | GAA 3943/4885RAPGEF4 431/4885ALDH1A1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.